This is a routine IP portfolio update with no trading implications. Monitor upcoming clinical data readouts for APR-1051 (ACESOT-1051 Phase 1) and any potential combination development for ATRN-119 for material catalysts.
Price Chart
Executive Summary
Aprea Therapeutics issued a press release on August 28, 2026, announcing an expansion of its intellectual property portfolio for its precision oncology programs. The filing is a routine update on patent counts and expiration dates for its WEE1 and ATR inhibitor programs, providing no new financial data, clinical results, or material changes to the business. This is a non-material, administrative update with no immediate impact on the stock.
Key Facts
- Aprea announced an update to its global intellectual property portfolio, reporting 28 issued and 30 pending patents.
- The WEE1 inhibitor program (APR-1051) has 2 pending U.S. applications, 1 pending U.S. provisional, 2 granted non-U.S. patents, and 12 pending non-U.S. applications; if granted, will expire in 2047.
- The ATR inhibitor program (ATRN-119) has 4 granted U.S. patents, 1 pending U.S. application, 22 granted non-U.S. patents, and 13 pending non-U.S. applications; granted patents expire 2035-2037, pending could extend to 2045.
- No financial figures, clinical data, or guidance were provided in the filing.
Financial Impact
No financial impact disclosed or estimable from this filing.
Risk Factors
- No new financial or operational risks disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-102795 |
| Document: 0001104659-26-102795-index.html | 0001104659-26-102795 |
| Document: 0001104659-26-102795.txt | 0001104659-26-102795 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers